β-内酰胺类和β-内酰胺酶抑制剂市场：依药物类别、给药途径、病患群体、应用和最终用户划分－2026-2032年全球市场预测

预计到 2025 年，β-内酰胺类和β-内酰胺酶抑制剂市值将达到 309.8 亿美元，到 2026 年将成长至 323.5 亿美元，到 2032 年将达到 425.8 亿美元，复合年增长率为 4.64%。

主要市场统计数据
基准年 2025	309.8亿美元
预计年份：2026年	323.5亿美元
预测年份 2032	425.8亿美元
复合年增长率 (%)	4.64%

权威概述了β-内酰胺类和β-内酰胺酶抑制剂的临床重要性、科学复杂性和策略背景。

β-内酰胺类抗生素及其辅助药物—β-内酰胺酶抑制剂，仍然是现代抗菌治疗的基石，支撑着从急诊医学到复杂住院患者管理等常规临床实践。已确立的药物类别－碳青霉烯类、头孢菌素类、单环胺基类和青霉素类－及其与不断演变的抗药性机制的相互作用，持续影响着治疗决策、监管重点以及研发投入。过去十年，临床医生和政策制定者透过重新聚焦联合治疗、合理用药方案以及标靶开发能够恢復传统β-内酰胺类抗生素活性的抑制剂，来应对日益严重的抗菌药物抗药性问题。

对重塑β-内酰胺类药物研发和临床应用的科学、监管、诊断和供应链因素进行综合分析。

在科学、监管和技术因素的驱动下，β-内酰胺类抗生素和β-内酰胺酶抑制剂的治疗模式正在经历一系列变化。在科学方面，化学家和生物学家正在改进抑制剂骨架，以扩大其对更多种类β-内酰胺酶的活性。同时，转化研究优先开发能够维持对多重抗药性革兰氏阴性菌疗效的联合治疗。这些进展与诊断准确性的提高并进。快速分子检测和以抗菌药物管理为重点的照护现场（POC​​）工具能够实现治疗的早期升级和靶向升级，从而改变处方模式并影响药物研发的优先顺序。

对关税趋势和贸易政策考量如何影响抗生素产品组合供应链的韧性、筹资策略和商业规划进行基于证据的评估。

影响贸易和关税的政策变化可能对复杂的药品供应链造成毁灭性打击，而围绕2025年美国关税的争论正促使相关人员重新评估其采购、生产和合约安排。由于活性药物成分（API）和关键中间体通常在地理位置集中的丛集生产，关税导致的进口成本增加和复杂的海关程序可能会波及采购预算、契约製造计划和库存策略。为此，製造商和买家正寻求透过增加API供应商的地理多元化、加强安全库存以及将关键生产过程到近岸地区来保护基本抗生素的供应免受政策变化的影响。

将药物类别、给药途径、患者人口统计特征、临床应用和最终用户趋势联繫起来的详细細項分析，有助于制定开发和商业化策略。

透过按药物类别、给药途径、患者类型、适应症和最终用户分析β-内酰胺类和β-内酰胺酶抑制剂领域的细分市场趋势，可以发现不同的机会和业务挑战。药物类别细分包括碳青霉烯类、头孢菌素类、单环胺基类和青霉素类。在碳青霉烯类药物中，多利培南、厄他培南、ImipenemMeropenem等不同分子表现出不同的抗菌频谱和药物动力学特征，从而影响医院的处方集决策和经验性治疗通讯协定。头孢菌素类涵盖第一代至第五代药物，每种药物对革兰氏阴性菌和革兰氏阳性菌的抗菌频谱均不同。这些世代差异显着影响抗药性模式及其在指引建议中的位置。青霉素，包括氨基青霉素、频谱青霉素和天然青霉素，在社区医疗保健和医院环境中继续发挥重要作用，与标靶抑制剂联合使用时，通常作为核心药物发挥作用。

详细的区域分析表明，临床实践、监管政策、生产能力和采购模式正在塑造世界主要地区的战略重点。

临床实务、法规结构、生产能力和公共卫生优先事项的区域差异，影响关键地区β-内酰胺类抗生素和β-内酰胺酶抑制剂疗法的应用、研发和供应。在美洲，监管机构和临床网络高度重视合理使用抗生素、以医院为中心的治疗路径，以及体现缩短住院时间和预防併发症等价值观的适应症选择。美国仍然是后期临床研发和先进诊断技术的中心，支付方越来越关注基于疗效的合约和真实世界数据，以此作为报销决策的依据。

影响公司如何开发、生产和销售β-内酰胺类疗法和互补抑制剂的策略性企业行为和伙伴关係模式。

抗生素和抑制剂领域的企业策略正朝着几个长期发展方向靠拢：风险共担的合作模式、聚焦研发管线、产品组合优化以及业务永续营运。创新製药公司越来越多地与专业生物技术公司和合约研究机构合作，以确保获得新型化学结构，并分担早期研发的成本和风险。同时，学名药和专利到期药生产商正努力透过优化生产效率和研发差异化製剂（例如高浓度静脉製剂和便于患者使用的口服减重疗法）来维持其临床疗效。

为产业、临床实务和政策制定者提供实际有效的建议，以加强抗生素的价值链，加速抗生素的普及应用，并保护其治疗价值。

产业、临床和政策制定者应采取务实且多管齐下的方法，在确保药物可及性的同时，兼顾治疗价值和商业性价值。首先，各机构应优先考虑价值链多元化。这包括认证多家活性原料药(API) 和製剂供应商，探索区域性生产方案，并实施稳健的库存管理和紧急时应对计画，以减轻政策和贸易相关干扰的影响。其次，调整研发组合，确保满足尚未满足的重大需求，并优先研发与快速分子诊断相容的联合治疗，可以加速药物推广应用，提高支付方的接受度。第三，企业应儘早投资建构符合医院和支付方决策标准的真实世界数据 (REW) 和药物经济学模型，以支持报销谈判和处方集。

一个透明、严谨的多面向研究框架，整合了临床证据、专家访谈、监管分析和供应链情境检验，以支持策略决策。

本分析所依据的研究采用多方法整合策略，旨在融合科学、临床、监管和营运观点。主要研究包括对感染疾病医生、医院药剂师、法规事务专业人员、生产专家和供应链经理进行结构化访谈，以了解第一线决策和营运限制。次要研究整合了同侪审查的临床文献、监管指导文件、临床试验註册资料和产品说明，以建构按适应症分類的疗效、安全性和使用模式的全面证据基础。此外，还分析了公共文件和产业报告，以评估关税和贸易政策趋势对采购和生产策略的潜在影响。

对策略挑战和未来优先事项进行简明扼要的整合，总结瞭如何将临床发现与营运系统和永续的治疗结果联繫起来。

抗生素抗药性、诊断技术创新、不断变化的监管环境以及供应链重组等多重压力，共同构成了一个复杂但可控的β-内酰胺类抗生素和β-内酰胺酶抑制剂的研发和应用环境。治疗的成功不仅取决于科学创新，还取决于展现实际的临床价值、维持可靠的供应链以及与合理的用药和诊断流程无缝衔接。那些将研发重点与诊断能力结合、投资于供应链韧性并积极与支付方和医疗系统合作的机构，将更有利于实现临床获益和永续的商业性成果。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：β-内酰胺类和β-内酰胺酶抑制剂市场：依药物类别划分

• 碳青霉烯类
  • 多利培南
  • 艾尔他培南
  • Imipenem
  • Meropenem
• 头孢菌素
  • 第五代头孢菌素
  • 第一代头孢菌素
  • 第四代头孢菌素
  • 第二代头孢菌素
  • 第三代头孢菌素
• 单环胺基类
• 青霉素
  • 氨基青霉素
  • 频谱青霉素
  • 天然青霉素

第九章 β-内酰胺类和β-内酰胺酶抑制剂市场：依给药途径划分

• 口服
  • 胶囊
  • 药片
• 肠外给药
  • 肌肉内部
  • 静脉注射

第十章：依病患类型分類的β-内酰胺类和β-内酰胺酶抑制剂市场

• 成年患者
  • 中年人
  • 老年人
  • 青年人
• 儿童患者
  • 青年
  • 儿童
  • 婴儿
  • 新生

第十一章 β-内酰胺类和β-内酰胺酶抑制剂市场：依应用领域划分

• 妇科感染疾病
• 腹腔内感染疾病
• 术中预防
• 呼吸道感染疾病
• 皮肤感染疾病
  • 蜂窝组织炎
  • 丹毒
  • 脓疱疮
• 尿道感染
  • 急性尿道感染
  • 慢性尿道感染

第十二章 β-内酰胺类和β-内酰胺酶抑制剂市场：依最终用户划分

• 学术机构
• 诊所
• 医院
• 研究机构

第十三章 β-内酰胺类和β-内酰胺酶抑制剂市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 β-内酰胺类和β-内酰胺酶抑制剂市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 β-内酰胺类和β-内酰胺酶抑制剂市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章：美国β-内酰胺类与β-内酰胺酶抑制剂市场

第十七章：中国β-内酰胺类和β-内酰胺酶抑制剂市场

第十八章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• AbbVie Inc.
• Aurobindo Pharma Limited
• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Company
• Centrient Pharmaceuticals Netherlands BV
• Cipla Ltd.
• Creative Diagnostics
• F. Hoffmann-La Roche AG
• Marubeni Corporation
• Melinta Therapeutics, LLC
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Protech Telelinks
• Qpex Biopharma, Inc. by Shionogi Inc.
• SciClone Pharmaceuticals（Holdings）Limited
• Sumitomo Pharma Co., Ltd.
• Thermo Fisher Scientific Inc.
• TOKU-E
• Venatorx Pharmaceuticals, Inc.
• Zai Lab Limited

The Beta Lactam & Beta Lactamase Inhibitors Market was valued at USD 30.98 billion in 2025 and is projected to grow to USD 32.35 billion in 2026, with a CAGR of 4.64%, reaching USD 42.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 30.98 billion
Estimated Year [2026]	USD 32.35 billion
Forecast Year [2032]	USD 42.58 billion
CAGR (%)	4.64%

An authoritative overview framing the clinical importance, scientific complexity, and strategic context of beta-lactam and beta-lactamase inhibitor therapeutics

Beta-lactam antibiotics and their companion beta-lactamase inhibitors remain foundational pillars of modern antimicrobial therapy, underpinning routine clinical practice from emergency care to complex inpatient management. The interplay between established drug classes such as carbapenems, cephalosporins, monobactams, and penicillins and evolving resistance mechanisms continues to shape therapeutic decision-making, regulatory priorities, and R&D investment. Over the past decade, clinicians and policy makers have responded to rising antimicrobial resistance with renewed emphasis on combination therapies, stewardship programs, and targeted development of inhibitors that restore the activity of legacy beta-lactams.

Concurrently, advances in molecular diagnostics, pharmacokinetics, and formulation science have refined how these agents are deployed across diverse patient populations and clinical settings. These technical and operational shifts are not discrete; they coalesce into a complex environment where scientific innovation must align with supply chain resilience, reimbursement structures, and public health imperatives. Against this backdrop, stakeholders require clear, actionable intelligence that synthesizes clinical evidence, regulatory signals, and system-level dynamics to inform product strategies, clinical development plans, and market access pathways. This report provides that structured perspective and equips decision-makers with the context necessary to navigate both persistent challenges and emerging opportunities.

A synthesized analysis of the scientific, regulatory, diagnostic, and supply chain forces reshaping the development and clinical deployment of beta-lactam-based therapies

The therapeutic landscape for beta-lactams and beta-lactamase inhibitors is undergoing a sequence of transformative shifts driven by scientific, regulatory, and technological forces. On the scientific front, chemists and biologists have refined inhibitor scaffolds to broaden activity against diverse beta-lactamases, while translational research has prioritized combinations that preserve efficacy against multidrug-resistant Gram-negative organisms. These advances are running in parallel with improvements in diagnostic precision: rapid molecular assays and stewardship-focused point-of-care tools are enabling earlier de-escalation or targeted escalation of therapy, thereby changing prescribing patterns and influencing drug development priorities.

Regulatory and payer environments are also evolving, with accelerated approval pathways and value-based contracting models encouraging innovation that demonstrably improves clinical outcomes or reduces hospital resource utilization. Manufacturing and supply chain strategies have shifted from cost-centric to resilience-centric models, catalyzed by global disruptions that highlighted the risks of concentrated production footprints. Finally, cross-sector collaboration among academia, biotech innovators, and larger pharmaceutical firms has become more common, enabling shared risk for difficult-to-develop molecules while leveraging complementary capabilities. Together, these shifts are enabling a more nuanced approach to antibiotic stewardship, clinical deployment, and commercial strategy that balances efficacy, access, and sustainability.

An evidence-based appraisal of how tariff dynamics and trade policy considerations are influencing supply chain resilience, sourcing strategies, and commercial planning for antibiotic portfolios

Policy shifts affecting trade and tariffs can exert outsized effects on complex pharmaceutical supply chains, and the discourse around United States tariffs in 2025 has prompted stakeholders to re-evaluate sourcing, manufacturing, and contractual arrangements. Pharmaceutical active pharmaceutical ingredients and key intermediates are often produced in geographically concentrated clusters; any tariff-driven increase in import costs or customs complexity can ripple through procurement budgets, contract manufacturing timelines, and inventory strategies. In response, manufacturers and purchasers have been exploring greater geographic diversification of API suppliers, increased safety stock, and nearshoring of critical production steps to insulate essential antibiotic supply from policy volatility.

Beyond direct cost implications, tariff dynamics influence strategic investment decisions. Developers weighing late-stage trials or scaling production may adjust timelines or negotiate alternate supply agreements to preserve margins and delivery reliability. Health systems and payers may respond by tightening sourcing criteria or prioritizing suppliers with demonstrable supply continuity. At the same time, tariffs can accelerate domestic capacity-building initiatives as governments and industry seek to reduce strategic dependence on single-source geographies; those initiatives include incentives for manufacturing upgrades, streamlined regulatory support for facility qualification, and public-private partnerships. Taken together, the cumulative impact of tariff policy considerations in 2025 and beyond has been to sharpen focus on supply chain resilience, to encourage investment in diversified manufacturing footprints, and to elevate contractual and operational risk management as core components of commercial planning.

In-depth segmentation intelligence linking drug class, administration route, patient demographics, clinical applications, and end-user dynamics to inform development and commercialization strategy

Segment-level dynamics within the beta-lactam and beta-lactamase inhibitor space reveal differentiated opportunities and operational imperatives when analyzed across drug class, route of administration, patient type, application, and end user. Drug class segmentation encompasses carbapenems, cephalosporins, monobactam, and penicillins. Within carbapenems, distinct molecules such as doripenem, ertapenem, imipenem, and meropenem exhibit varied spectrum and pharmacokinetic profiles that influence hospital formulary decisions and empirical therapy protocols. Cephalosporins span first- through fifth-generation agents with differing Gram-negative and Gram-positive coverage, and these generational differences meaningfully affect positioning relative to resistance patterns and guideline recommendations. Penicillins, including aminopenicillins, extended-spectrum penicillins, and natural penicillins, retain key roles across community and hospital settings and often serve as backbone agents when coupled with targeted inhibitors.

Route-of-administration segmentation separates oral administration and parenteral administration. Oral options, delivered as capsules or tablets, support outpatient stewardship strategies, step-down therapy, and continuity of care post-discharge, while parenteral administration via intramuscular or intravenous routes remains essential for severe infections and inpatient management. Patient-type segmentation distinguishes adult and pediatric populations, with adults further stratified into young, middle-aged, and senior cohorts and pediatric classification including adolescents, children, infants, and neonates; each demographic subgroup presents unique pharmacokinetic considerations, dosing strategies, and safety profiles that affect clinical development and labeling decisions. Application-based segmentation covers gynecological, intra-abdominal, intraoperative prophylaxis, respiratory, skin, and urinary tract infections; skin indications further break down into cellulitis, erysipelas, and impetigo, and urinary tract infections distinguish acute from chronic presentations. These clinical use-cases drive differentiation in formulation, duration of therapy, and evidence generation needs. Finally, end-user segmentation includes academic institutions, clinics, hospitals, and research laboratories, each with distinct procurement cycles, clinical governance frameworks, and evidence thresholds for adopting new combinations or formulations. Understanding these layered segments enables developers and commercial teams to align clinical trials, regulatory strategies, and go-to-market plans with the nuanced requirements of prescribers, payers, and institutional buyers.

A nuanced regional synthesis showing how clinical practice, regulatory policy, manufacturing capacity, and procurement models shape strategic priorities across major global geographies

Regional variation in clinical practice, regulatory frameworks, manufacturing capacity, and public health priorities shapes the adoption, development, and supply of beta-lactam and beta-lactamase inhibitor therapies across major geographies. In the Americas, regulatory authorities and clinical networks place strong emphasis on antimicrobial stewardship, hospital-centric treatment pathways, and coverage decisions that reflect value in reducing length of stay and preventing complications. The United States remains a hub for late-stage clinical development and advanced diagnostics, with payers increasingly focused on outcomes-based contracting and real-world evidence to inform reimbursement.

Europe, Middle East & Africa present a heterogeneous landscape where national-level procurement practices, variable access to diagnostics, and differing reimbursement models lead to distinct regional strategies. Several European countries emphasize centralized procurement and tight stewardship protocols, while some Middle East and African markets prioritize access and capacity-building, creating avenues for tailored access programs and tiered pricing arrangements. Asia-Pacific combines dynamic demand with concentrated manufacturing capabilities and regulatory modernization. Several markets in Asia-Pacific have become major production centers for APIs and finished formulations, while others are substantial demand centers owing to high infectious disease burden and growing healthcare infrastructure investment. Regional regulatory harmonization efforts, clinical trial site availability, and local manufacturing incentives all play roles in shaping how companies prioritize launches, scale production, and structure distribution networks. Cross-regional strategies that account for these differences in clinical practice, policy environment, and industrial capability will be essential for effective global deployment of new therapeutic combinations and stewardship-aligned access models.

Strategic corporate behaviors and partnership models that are shaping how organizations develop, manufacture, and commercialize beta-lactam therapies and complementary inhibitors

Company strategies in the antibiotic and inhibitor domain are coalescing around several enduring themes: risk-sharing collaborations, focused pipelines, portfolio optimization, and operational resilience. Innovator organizations are increasingly partnering with specialized biotech firms or contract research organizations to access novel chemotypes and to share the costs and risks of early development. Simultaneously, generics and off-patent manufacturers are optimizing production efficiency and pursuing differentiated formulations, such as high-concentration intravenous presentations or patient-friendly oral step-down options, to maintain clinical relevance.

Across the competitive landscape, firms are prioritizing assets that address high unmet clinical need or that restore activity to existing beta-lactams in the face of specific resistance mechanisms. Licensing agreements and co-development partnerships enable speed-to-market while spreading technical risk, and companies are investing in manufacturing flexibility to adapt to regional demand and policy shifts. Contract manufacturing organizations and research laboratories play pivotal roles in scaling production and supporting complex analytical validation. Moreover, firms are increasingly integrating real-world evidence generation and health-economic modeling into development plans to support reimbursement negotiations and to demonstrate comparative value to payers and hospital procurement committees. Taken together, these strategic behaviors underscore a sector moving toward more collaborative, evidence-driven, and operationally resilient models of product development and commercialization.

Practical and high-impact recommendations for industry, clinical, and policy leaders to strengthen supply chains, accelerate adoption, and safeguard therapeutic value in antibiotics

Leaders across industry, clinical practice, and policy should adopt a pragmatic, multi-dimensional approach to capture therapeutic and commercial value while safeguarding access. First, organizations should prioritize supply chain diversification by qualifying multiple API and finished-dosage form suppliers, exploring regional manufacturing options, and implementing robust inventory and contingency planning to mitigate policy or trade-related disruptions. Second, aligning R&D portfolios to prioritize combinations that demonstrably address high clinical unmet need and that are compatible with rapid molecular diagnostics will enhance adoption and payer receptivity. Third, companies should invest in early generation of real-world evidence and pharmacoeconomic models tailored to hospital and payer decision criteria to support reimbursement discussions and formulary inclusion.

Fourth, forging partnerships with diagnostic developers, health systems, and stewardship coalitions will improve appropriate use and strengthen clinical value propositions. Fifth, engage proactively with regulatory agencies to explore streamlined pathways and adaptive trial designs that can accelerate access for high-need indications while maintaining rigorous safety and efficacy standards. Sixth, develop tailored regional access plans that account for local formularies, procurement mechanisms, and capacity constraints, leveraging tiered pricing or managed entry agreements where appropriate. Finally, embed antimicrobial stewardship principles into commercial strategies to ensure long-term efficacy and societal value of new therapeutic combinations. These coordinated actions will help organizations balance near-term commercial imperatives with the broader public health mandate to preserve antibiotic effectiveness.

A transparent and rigorous multi-method research framework integrating clinical evidence, expert interviews, regulatory analysis, and supply chain scenario testing to inform strategic decisions

The research underpinning this analysis draws on a multi-method approach designed to integrate scientific, clinical, regulatory, and operational perspectives. Primary research included structured interviews with infectious disease clinicians, hospital pharmacists, regulatory affairs experts, manufacturing specialists, and supply chain managers to capture frontline decision-making and operational constraints. Secondary research synthesized peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and product monographs to build a comprehensive evidence base on efficacy, safety, and indication-specific use patterns. In addition, public policy documents and trade reports were analyzed to assess potential impacts of tariff and trade policy developments on procurement and manufacturing strategies.

Supply chain mapping exercises and scenario-based stress tests were employed to identify vulnerabilities and mitigation levers across sourcing, production, and distribution. Health technology assessment frameworks and pharmacoeconomic modeling informed the evaluation of payer-relevant value drivers without producing quantitative market estimations. Where appropriate, cross-validation with expert panels ensured that conclusions reflect clinical reality and operational feasibility. This convergent methodology supports robust qualitative insights while preserving transparency about data sources and analytical assumptions.

A concise synthesis of strategic imperatives and forward-looking priorities that summarize how to translate clinical insight into operational readiness and sustainable therapeutic impact

The convergence of antimicrobial resistance pressures, diagnostic innovation, regulatory evolution, and supply chain recalibration has created a complex but navigable landscape for beta-lactam and beta-lactamase inhibitor development and deployment. Therapeutic success will depend not only on scientific novelty but also on the ability to demonstrate actionable clinical value, maintain reliable supply, and integrate seamlessly with stewardship and diagnostic workflows. Organizations that align R&D priorities with diagnostic capabilities, that invest in supply chain resilience, and that engage proactively with payers and health systems will be positioned to deliver both clinical benefit and sustainable commercial performance.

Looking ahead, the sector is likely to favor pragmatic innovation that restores or extends the utility of established beta-lactams while minimizing collateral selection pressure and preserving access. Collaborative models that distribute risk and leverage complementary competencies will remain central to advancing novel inhibitors into practice. Ultimately, stakeholders who translate deep clinical insight into operational readiness and evidence-aligned value propositions can simultaneously advance patient outcomes and create durable strategic advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class

• 8.1. Carbapenems
  • 8.1.1. Doripenem
  • 8.1.2. Ertapenem
  • 8.1.3. Imipenem
  • 8.1.4. Meropenem
• 8.2. Cephalosporins
  • 8.2.1. Fifth-Generation Cephalosporins
  • 8.2.2. First-Generation Cephalosporins
  • 8.2.3. Fourth-Generation Cephalosporins
  • 8.2.4. Second-Generation Cephalosporins
  • 8.2.5. Third-Generation Cephalosporins
• 8.3. Monobactam
• 8.4. Penicillins
  • 8.4.1. Aminopenicillins
  • 8.4.2. Extended-Spectrum Penicillins
  • 8.4.3. Natural Penicillins

9. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration

• 9.1. Oral Administration
  • 9.1.1. Capsules
  • 9.1.2. Tablets
• 9.2. Parenteral Administration
  • 9.2.1. Intramuscular
  • 9.2.2. Intravenous

10. Beta Lactam & Beta Lactamase Inhibitors Market, by Patient Type

• 10.1. Adult Patients
  • 10.1.1. Middle-Aged Adults
  • 10.1.2. Senior Adults
  • 10.1.3. Young Adults
• 10.2. Pediatric Patients
  • 10.2.1. Adolescents
  • 10.2.2. Children
  • 10.2.3. Infants
  • 10.2.4. Neonates

11. Beta Lactam & Beta Lactamase Inhibitors Market, by Application

• 11.1. Gynecological Infections
• 11.2. Intrabdominal Infections
• 11.3. Intraoperative Prophylaxis
• 11.4. Respiratory Infections
• 11.5. Skin Infections
  • 11.5.1. Cellulitis
  • 11.5.2. Erysipelas
  • 11.5.3. Impetigo
• 11.6. Urinary Tract Infections
  • 11.6.1. Acute UTI
  • 11.6.2. Chronic UTI

12. Beta Lactam & Beta Lactamase Inhibitors Market, by End User

• 12.1. Academic Institutions
• 12.2. Clinics
• 12.3. Hospitals
• 12.4. Research Laboratories

13. Beta Lactam & Beta Lactamase Inhibitors Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Beta Lactam & Beta Lactamase Inhibitors Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Beta Lactam & Beta Lactamase Inhibitors Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Beta Lactam & Beta Lactamase Inhibitors Market

17. China Beta Lactam & Beta Lactamase Inhibitors Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. AbbVie Inc.
• 18.6. Aurobindo Pharma Limited
• 18.7. Bio-Rad Laboratories, Inc.
• 18.8. Bristol-Myers Squibb Company
• 18.9. Centrient Pharmaceuticals Netherlands B.V.
• 18.10. Cipla Ltd.
• 18.11. Creative Diagnostics
• 18.12. F. Hoffmann-La Roche AG
• 18.13. Marubeni Corporation
• 18.14. Melinta Therapeutics, LLC
• 18.15. Merck KGaA
• 18.16. Novartis AG
• 18.17. Pfizer Inc.
• 18.18. Protech Telelinks
• 18.19. Qpex Biopharma, Inc. by Shionogi Inc.
• 18.20. SciClone Pharmaceuticals (Holdings) Limited
• 18.21. Sumitomo Pharma Co., Ltd.
• 18.22. Thermo Fisher Scientific Inc.
• 18.23. TOKU-E
• 18.24. Venatorx Pharmaceuticals, Inc.
• 18.25. Zai Lab Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIFTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FIRST-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY FOURTH-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SECOND-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY THIRD-GENERATION CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY AMINOPENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY EXTENDED-SPECTRUM PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NATURAL PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SENIOR ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY YOUNG ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GYNECOLOGICAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRABDOMINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAOPERATIVE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 120. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 121. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 124. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CELLULITIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 126. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 127. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY REGION, 2018-2032 (USD MILLION)
• TABLE 129. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 130. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY IMPETIGO, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 131. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 132. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 133. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 134. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACUTE UTI, BY REGION, 2018-2032 (USD MILLION)
• TABLE 136. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACUTE UTI, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 137. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACUTE UTI, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 138. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHRONIC UTI, BY REGION, 2018-2032 (USD MILLION)
• TABLE 139. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHRONIC UTI, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 140. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CHRONIC UTI, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 141. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 142. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 143. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 144. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 145. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 146. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 148. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 149. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 150. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 151. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 152. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 153. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 154. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 155. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 156. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 157. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 158. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 159. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 160. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 161. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 162. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 163. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 164. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 165. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 166. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 167. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 168. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 169. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 170. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 172. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 174. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 176. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 178. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 180. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 182. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 184. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 186. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 188. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 190. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 192. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 194. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 196. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 198. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 215. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 216. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 217. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 218. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 219. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 220. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 221. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 222. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 223. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 224. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 225. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 226. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 227. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 228. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 229. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 230. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 232. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 234. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 236. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 238. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 240. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 242. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 244. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 245. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 246. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 247. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 248. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 249. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 250. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 251. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 252. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 253. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
• TABLE 254. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
• TABLE 255. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
• TABLE 256. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 257. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 258. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
• TABLE 259. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 260. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 261. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 262. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
• TABLE 263. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
• TABLE 264. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
• TABLE 265. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 266. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MIL